Provider
Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors - Commercial - Effective Date 02/01/2025
Program effective Date: Feb 01, 2025
Program effective Date: Feb 01, 2025
Program effective Date: Feb 01, 2025
Program effective Date: Feb 01, 2025
Program effective Date: Feb 01, 2025
Program effective Date: Feb 01, 2025